Inotiv_Logo_CMYK.png
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 08, 2022 16:10 ET | Inotiv, Inc.
WEST LAFAYETTE, Ind., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and...
Untitled-1
Endure Biotherapeutics, Inc. Announces Publication of Founder’s Seminal Work Regarding Colonizing Biotherapeutics
August 15, 2022 23:41 ET | Endure Biotherapeutics, Inc.
San Diego, Aug. 15, 2022 (GLOBE NEWSWIRE) --    FOR IMMEDIATE RELEASE Endure Biotherapeutics, Inc. Announces Publication of Founder’s Seminal Work Regarding Colonizing Biotherapeutics Zarrinpar...
NeuroSigma.png
NeuroSigma Announces King’s College London Team Receives MHRA Approval to Commence Largest Clinical Trial of eTNS for Pediatric ADHD to Date
April 07, 2022 11:00 ET | NeuroSigma, Inc.
Double-blind randomized controlled trial of eTNS for pediatric ADHD will enroll up to 150 participants at two sites in London and Southampton NeuroSigma’s Monarch eTNS System and electric patches to...
ProgenityLogo.jpg
Progenity Announces Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology
January 11, 2022 06:30 ET | Progenity, Inc.
SAN DIEGO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
ProgenityLogo.jpg
Progenity Announces Acceptance of Two Abstracts on Treatment of Gastrointestinal Disorders at ECCO’22
January 05, 2022 06:30 ET | Progenity, Inc.
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Inotiv_Logo_CMYK.png
Inotiv, Inc. and Synexa Life Sciences Sign Letter of Intent to Establish Center of Excellence for Biotherapeutics and Biomarkers
January 04, 2022 08:33 ET | Inotiv, Inc.
-- Expected to establish a leading global provider of full-spectrum, preclinical and clinical biotherapeutics and biomarker analysis solutions -- -- Expected to enhance scale, broaden customer base...
ProgenityLogo.jpg
Progenity to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference
January 03, 2022 06:30 ET | Progenity, Inc.
SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
ProgenityLogo.jpg
Progenity Completes Exit from Laboratory Business with Sale of Affiliate Lab
December 20, 2021 16:05 ET | Progenity, Inc.
SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
ProgenityLogo.jpg
Progenity Announces New Patent for Single-Molecule Detection Technology
December 02, 2021 06:30 ET | Progenity, Inc.
SAN DIEGO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the fields of gastrointestinal health and oral biotherapeutics, today announced a...
ProgenityLogo.jpg
Progenity Strengthens its Liquidity Position
November 23, 2021 06:30 ET | Progenity, Inc.
Company received more than $44 million in warrant exercises since August 2021. Current liquidity position provides runway to achieve critical research and development milestones through 2022. SAN...